Caribou Biosciences, Inc. (CRBU)Healthcare | Biotechnology | Berkeley, United States | NasdaqGS
1.80 USD
-0.13
(-6.494%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.83 +0.03 (1.633%) ⇧ (July 13, 2026, 7:20 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:20 a.m. EDT
The fundamental reality here is stark: despite a 'strong buy' analyst consensus driven by a $32 price target, the business is deteriorating. Revenue growth is negligible at 1.9%, while the company burns cash aggressively, resulting in a -10.9% operating margin and negative free cash flow. The balance sheet is fragile with negative ROE and ROA, and the stock has suffered a catastrophic -90% decline over the last four years. The recent price action shows a slight recovery from lows, but the technicals remain weak relative to the 200-day average. The disconnect between the analyst targets and the actual financials is dangerous. Analysts are pricing in a miracle turnaround that the current fundamentals do not support. The options market reflects this tension: while call buyers are optimistic about a breakout, the extreme put IV suggests the market is terrified of a continued grind lower. For a biotech stock with no dividends and a history of multi-year destruction, the risk-reward profile is unfavorable. The 'strong buy' rating appears to be a function of the low share price making the absolute dollar gain look large, rather than a reflection of superior business quality. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.090856 |
| MSTL_62_113 | 0.096692 |
| MSTL_113 | 0.100524 |
| MSTL_62 | 0.111758 |
| AutoETS | 0.113846 |
| AutoARIMA | 0.113849 |
| MSTL | 0.120102 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 5.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.544 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.413 |
| Revenue per Share | 0.119 |
| Market Cap | 178,525,040 |
| Forward P/E | -1.29 |
| Beta | 2.37 |
| Website | https://cariboubio.com |
As of July 11, 2026, 3:20 a.m. EDT: Speculators are heavily skewed toward calls, with open interest concentrated in out-of-the-money strikes ($2.50 and $5.00) across various expirations, suggesting a speculative bet on a binary event or pipeline catalyst. However, implied volatility is significantly elevated for puts (2.92% vs 0.70% for calls), indicating deep fear regarding downside protection. The massive put volume at the $2.50 strike suggests a specific resistance level where traders are hedging against a failure to break out, creating a 'long gamma' squeeze scenario if the price rallies, but a heavy ceiling if it stalls.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.13235295 |
| Address1 | 2,929 7th Street |
| Address2 | Suite 105 |
| All Time High | 32.645 |
| All Time Low | 0.66 |
| Ask | 2.26 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 3,471,290 |
| Average Daily Volume3 Month | 2,065,173 |
| Average Volume | 2,065,173 |
| Average Volume10Days | 3,471,290 |
| Beta | 2.365 |
| Bid | 1.34 |
| Bid Size | 2 |
| Book Value | 1.052 |
| City | Berkeley |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.8 |
| Current Ratio | 6.221 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.91 |
| Day Low | 1.76 |
| Debt To Equity | 26.413 |
| Display Name | Caribou Biosciences |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -114,156,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.77 |
| Enterprise To Revenue | 7.841 |
| Enterprise Value | 87,845,032 |
| Eps Current Year | -1.24667 |
| Eps Forward | -1.4 |
| Eps Trailing Twelve Months | -1.42 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9195 |
| Fifty Day Average Change | -0.11950004 |
| Fifty Day Average Change Percent | -0.06225582 |
| Fifty Two Week Change Percent | 13.235294 |
| Fifty Two Week High | 3.535 |
| Fifty Two Week High Change | -1.7350001 |
| Fifty Two Week High Change Percent | -0.49080625 |
| Fifty Two Week Low | 1.38 |
| Fifty Two Week Low Change | 0.41999996 |
| Fifty Two Week Low Change Percent | 0.30434778 |
| Fifty Two Week Range | 1.38 - 3.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,047,000,000 |
| Float Shares | 94,810,679 |
| Forward Eps | -1.4 |
| Forward P E | -1.2857143 |
| Free Cashflow | -63,509,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 97 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -81,400,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08912 |
| Held Percent Institutions | 0.37747002 |
| Implied Shares Outstanding | 99,180,575 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. |
| Long Name | Caribou Biosciences, Inc. |
| Market | us_market |
| Market Cap | 178,525,040 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_272189231 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -133,219,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 190,922,606 |
| Number Of Analyst Opinions | 7 |
| Open | 1.9 |
| Operating Cashflow | -101,251,000 |
| Operating Margins | -10.9637 |
| Payout Ratio | 0.0 |
| Phone | 510 982 6030 |
| Post Market Change | 0.029399991 |
| Post Market Change Percent | 1.6333328 |
| Post Market Price | 1.8294 |
| Post Market Time | 1,783,984,822 |
| Previous Close | 1.925 |
| Price Eps Current Year | -1.4438463 |
| Price Hint | 4 |
| Price To Book | 1.7110265 |
| Price To Sales Trailing12 Months | 15.935468 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.099 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.125 |
| Regular Market Change Percent | -6.49351 |
| Regular Market Day High | 1.91 |
| Regular Market Day Low | 1.76 |
| Regular Market Day Range | 1.76 - 1.91 |
| Regular Market Open | 1.9 |
| Regular Market Previous Close | 1.925 |
| Regular Market Price | 1.8 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,954,826 |
| Return On Assets | -0.34687 |
| Return On Equity | -0.8346 |
| Revenue Growth | 0.019 |
| Revenue Per Share | 0.119 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 99,180,575 |
| Shares Percent Shares Out | 0.0971 |
| Shares Short | 9,625,837 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,450,323 |
| Short Name | Caribou Biosciences, Inc. |
| Short Percent Of Float | 0.1011 |
| Short Ratio | 3.88 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRBU |
| Target High Price | 32.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 10.0 |
| Total Cash | 117,626,000 |
| Total Cash Per Share | 1.186 |
| Total Debt | 26,946,000 |
| Total Revenue | 11,203,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.9369 |
| Two Hundred Day Average Change | -0.13690007 |
| Two Hundred Day Average Change Percent | -0.070679985 |
| Type Disp | Equity |
| Volume | 1,954,826 |
| Website | https://cariboubio.com |
| Zip | 94,710 |